Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 5Endocrine 2

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Differentiated Thyroid Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 15lutetium Lu 177 dotatate 14Specimen Handling 14cabozantinib 10Nivolumab 10pembrolizumab 8Everolimus 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4Cyclophosphamide 4CTLA-4 Antigen 4fluorodopa F 18 3fludarabine 3dabrafenib 3cemiplimab 3atezolizumab 3Temozolomide 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Iodine-124 × Endocrine × 90 days × Clear all
NCT01704586 2026-05-12

CLERAD-PROBE

University of Wuerzburg

Phase NA Active not recruiting
340 enrolled
EndocrineHead & Neck

Differentiated Thyroid Carcinoma

NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡